Supplemental Figures for:
Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib
Wei-Yu Liao et al.

Figure S1. Kaplan–Meier survival curves of overall survival in a) patients with post-operative recurrence and newly diagnosed advanced NSCLC (P=0.018, Log-rank test) , b) in patients with ECOG ≥2 and ECOG <2 (P<0.001, Log-rank test); progression free survival in c) patients with post-operative recurrence and newly diagnosed advanced NSCLC (P=0.12, Log-rank test), d) in patients with ECOG ≥2 and ECOG <2 (P=0.001, Log-rank test)

Supplemental Figures for:
Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib
Wei-Yu Liao et al.

Figure S2. Kaplan–Meier survival curves of progression free survival in a) patients with Exon 19 deletion and L858R mutation (P=0.649, Log-rank test) , b) in patients with smoking index ≥ 20 pack-year and smoking index < 20 pack-year (P=0.362, Log-rank test), c) in patients with chronic hepatitis C, without chronic hepatitis C and unknown HCV status (P=0.39, Log-rank test), d) in patients with liver metastasis and without liver metastasis (P<0.001, Log-rank test)

Supplemental Figures for:
Real World Data on Prognostic Factors for Overall Survival in EGFR mutation-positive Advanced NSCLC Patients Treated with first-line Gefitinib
Wei-Yu Liao et al.

Figure S3. Kaplan–Meier survival curves of overall survival in patients without hepatotoxicity, with grade I hepatotoxicity and grade II hepatotoxicity